A 96-week, two-arm, randomized, single-masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy (CONDOR)

drug protocol number
CRTH258D2301
drug sponsor
Novartis
drug study
Brolucizumab
drug trial site
DESH
drug status
Completed
drug phase